









SUPPLEMENTARY INFORMATION

STAG2 regulates interferon signaling in melanoma via enhancer loop reprogramming







Zhaowei Chu^{1,2,16}, Lei Gu^{3,16,*}, Yeguang Hu^{1,16}, Xiaoyang Zhang^{4,16}, Man Li¹, Jiajia Chen^{5,6}, Da Teng¹, Man Huang⁷, Che-Hung Shen⁸, Li Cai⁹, Toshimi Yoshida¹, Yifeng Qi¹⁰, Zhixin Niu³, Austin Feng¹, Songmei Geng¹¹, Dennie T. Frederick¹², Emma Specht¹², Adriano Piris¹³, Ryan J. Sullivan¹², Keith T. Flaherty¹², Genevieve M. Boland¹⁴, Katia Georgopoulos¹, David Liu^{5,6}, Yang Shi^{7,15}, Bin Zheng^{1,*}




Supplementary Figure 1. Characterization of STAG2 binding sites in M14 melanoma cells by ChIP-seq. **a** High correlation of ChIP-seq data between biological replicates. High Spearman's correlation of the reads distribution from ChIP-seq experiments was observed between two biological replicates of M14 cells without (WT) or with (KD) STAG2 knockdown. Spearman correlation is calculated with reads per million (RPM) in each 10Kb window throughout the whole genome. **b** Examples of loss of STAG2 binding sites. Bigwig files for each sample is uploaded into IGV. Three representatives on loss of STAG2 binding sites are shown. **c** Overlap of STAG2 differential binding sites between two biological replicates. **d** The genomic distribution of differential binding sites for STAG1 and STAG2.

a**b****c****d**




Supplementary Figure 2. Characterization of STAG2 to STAG1 switch sites and non-switch sites in M14 cells. **a** Distribution of overlap between randomly simulated differential STAG1 and STAG2 sites. Red bar is the observed overlap sites. Empirical P value is 0.001, and is calculated based on 1000 times permutation test. **b** General genomic distribution of switch and non-switch STAG2 sites. **c** Fine mapping of the switch and non-switch STAG2 sites. **d** Motif enriched at switched and non-switch STAG2 sites.










Supplementary Figure 3. STAG2 inactivation leads to reorganization of chromosomal folding. **a** Representative heatmap for the global change of contact probability on chromosome 12 upon STAG2 knockdown in M14 cells. Reddish represents impaired contacts between genomic loci, and bluish represents enhanced contacts. **b** A representative example of fine-scale compartment changes between M14 cells without (WT) and with (KD) STAG2 knockdown. **c** Bar plot for average intra-chromosome contact probability within compartment A (AA) and B (BB), and across compartments (AB) in STAG2 WT and KD cells. **d** Bar plot for average inter-chromosome contact probability within compartment A (AA) and B (BB), and across compartments (AB) in STAG2 WT and KD cells. **e-f** Average contact probability at different genomic distance in STAG2 WT and KD cells, using 1Mb (**e**) or 500kb (**f**) or as window sizes.




Supplementary Figure 4. STAG2 inactivation is associated with disruption of TAD boundaries. **a** Distribution of TAD length in A/B compartments in M14 cells without (WT) and with (KD) STAG2 knockdown (n= 1671, 2010, 1378, 2002 TADs in WT-A, WT-B, KD-A, KD-B, respectively). P value is 2.324e-15 (WT-A VS WT-B), 3.383e-17 (KD-A VS KD-B), 2.378e-13 (WT-A VS KD-A), 2.481e-13 (WT-B VS KD-B) and is based on two-sided *wilcox*-test. **b** TAD length is significantly different between STAG2 WT (n=3672 TADs) and KD (n=3423 TADs) cells, as cross-validated by TADbit. P value is 2.473e-11 and is based on two-sided *wilcox*-test. **c** Overview of changes in TADs upon STAG2 knockdown. Lost represents TADs disappeared in STAG2 KD cells; gain represents newly formed TADs in STAG2 KD cells; overlap represents TADs showing up in both WT and KD cells. **d** Schematic representation of different types of TAD movements for overlap TADs upon knockdown of STAG2. **e** Percentages of different types of TAD movements within overlap TADs. **f** Meta plots of gene expression at boundaries of both variable TADs and stable TADs. Statistical significance is determined as: ns $P > 0.05$; * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$. The box plot is defined by bounds at the 25th percentile and 75th percentile, centre at 50th percentile, the minima and maxima are at the 10th percentile and 90th percentile.






Supplementary Figure 5. Insulation score across TAD boundaries. **a** Proportion of different types of TAD boundary changes upon STAG2 knockdown (KD). **b** Insulation profiles at 1 Mb resolution between variable and stable boundaries upon STAG2 KD. **c** Representative heat map matrices for changes in TAD boundaries at 250 kb resolution with insulation scores shown below.




Supplementary Figure 6. Analyses of H3K27ac associated DNA loops and super-enhancers in M14 cells. **a** High Spearman's correlation of the reads distribution from H3K27ac HiChIP experiments is observed between two biological replicates of M14 cells without (WT) or with (KD) STAG2 knockdown. Spearman correlation is calculated with reads per million (RPM) in each 10Kb window throughout the whole genome. **b** Box plot of loop length for enhanced (n= 9115 loops) and impaired loops (n= 11327 loops) upon STAG2 knockdown. The box plot is defined by bounds at the 25th percentile and 75th percentile, centre at 50th percentile, the minima and maxima are at the 10th percentile and 90th percentile. **c** Percentages of four groups of H3K27ac associated DNA loops in M14 WT and KD cells. PE represents promoter-enhancer interaction; EE represents enhancer-enhancer interaction; PP represents promoter-promoter interaction; other represents loops with either anchor located outside of enhancer or promoter. An enhancer is defined by a H3K27ac peak of which the genomic location is outside of a promoter. A promoter is defined by the 1kb upstream of a transcriptional start site. **d** Percentage of the same four groups of interactions within enhanced or impaired H3K27ac associated DNA loops upon STAG2 knockdown. **e** Motifs enriched at gain, lost and maintained super-enhancers upon STAG2 KD in M14 cells. **f** Examples of gain, lost and maintained super-enhancers in M14 WT and KD cells. **g** Metaplot of H3K27AC signals across three types of super enhancers upon STAG2 KD.



Supplementary Figure 7. Regulation of IRF9 and PD-L1 expression by STAG2 in melanoma cells. **a-b** GSEA enrichment plots depicting the enrichment of IFN α - (p=2.117e-25, q=2.367e-23) (**a**) and IFN γ response (p=2.341e-25, q=2.911e-23) (**b**) gene sets in M14 STAG2 KD cells. P value is the probability under the null distribution of obtaining an ES value that is as strong or stronger than that observed for the experiment under the permutation-generated null distribution. Q value is corrected by multiple comparisons at a false discovery rate (FDR) of 0.25. **c** Volcano plot of differentially expressed genes from RNA-seq data, with IRF9 indicated by the arrow. **d-e** M14 cells were transfected with STAG1 (**d**) or CTCF (**e**) shRNAs before subjected for immunoblotting with indicated antibodies. **f-h** Expression of a shRNA-refractory mutant of STAG2 rescued the effects of STAG2 knockdown on IRF9 and PD-L1 expression in M14 melanoma cells. Immunoblotting analyses (**f**) and flow cytometry analyses (**g,h**) were performed as indicated. **i** Immunoblotting analyses of STAG2, IRF9 and PD-L1 in several parental (P) and BRAF inhibitor-resistant (BR) melanoma cell lines. **j** Ectopic expression of STAG2 in WM902 BR cells increased the protein levels of IRF9 and PD-L1. **k** Quantification analyses (normalized to GAPDH) of data in **j**. **l-o** Quantifications of STAG2 knockdown by Western blot (**l**), RT-PCR (**m**) and RNA-seq (**n**) analyses, and IRF9 CRISPR knockout by Western blot analysis (**o**) in M14 cells. Data in **d-f,i-j** are representative of three independent experiments with similar results. Data in **h, k-o** are presented as mean \pm SEM. P values were determined by paired two-tailed t-tests, *P < 0.05; **P < 0.01; ***P < 0.001.



Supplementary Figure 8. Hi-C signal for the expanded TAD involving IRF9 regulation. a-b Location of anchors for a gain of chromatin interaction upon STAG2 knockdown (KD) in M14 cells. Left and right anchors are located around CTCF binding sites and overlapped with H3K27AC peak regions. **c** Representative contact frequency heatmap at 100 kb resolution showing an expanded TAD boundary from the right side of IRF9, leading to a new interaction formed between IRF9 and GMPR2 loci identified by HiChIP upon STAG2 KD.



b


sgRNA NGG STAG2 binding site

WT AAGATCGCGGCTCACTGCCACCTCCCGTCTACTGGGCGGGGCGCCTCTTCTGTTTT.....CCTCACGGGAGTGACGGGGCTTCTCCG

Δ SiteA #62 AAGATCGCGGCTCACTGCCACCTCCCGTCT.....CGGGGCGCCTCTTCTGTTTT.....GGGAGTGACGGGGCTTCTCCG


Δ SiteA #74 AAGATCGCGGCT.....CGGGGCGCCTCTTCTGTTTT.....GCTTCTCCG

Δ SiteA #82 AAGATCGCGGCTCACTGCCACCTCCCGTCT.....CGGGGCGCCTCTTCTGTTTT.....GGGAGTGACGGGGCTTCTCCG




Supplementary Figure 9. CRISPR/Cas9-mediated deletion of the STAG2 binding sites in the IRF9 region. **a** Schematic diagram indicates the positions of two STAG2 binding sites in the IRF9 region. **b** Sequencing results for M14 cell clones with CRISPR-engineered deletion of Site A or wild-type (WT) control. **c** Effects of CRISPR-engineered deletion of Site B on the mRNA expression levels of IRF9 and PD-L1 (n=3). Data in **c** are presented as mean \pm SEM. *P* values were determined by unpaired two-tailed t-tests. ns *P* > 0.05.




a



b



Supplementary Figure 10. Expression levels of STAG2 and PD-L1 in human melanoma samples. **a** Relationship between STAG2 mRNA level and PD-L1 mRNA level in TCGA SKCM patients ($n=473$) in the unadjusted analysis. The Spearman's correlation coefficient R value and two-sided P value are shown. **b** Median STAG2 mRNA expression level is higher in progressors (median = 7.05) compared to responders (median = 6.81) in a cohort of PD-1 ICB treated metastatic melanoma patients (Schadendorf cohort, $n = 103$ patients, 47 responders (CR/PR as best radiographic response to treatment) and 56 progressors (PD as best radiographic response to treatment), but the difference is not statistically significant (two-tailed Mann–Whitney–Wilcoxon (MWW), $P = 0.17$).



Supplementary Figure 11. Gating strategy for flow cytometry analysis of PD-L1 surface expression. Live cells were identified by using SSC-A, FSC-A, and 7-AAD. PD-L1⁺ cells were identified by using an isotype control.

Supplementary Table 1. Characterization of STAG1/2 switch and non-switch sites in the context of TAD domains, boundaries, promoters and enhancers.

| Variable | Switch | Non-switch | P value | OR |
|--------------|--------|------------|-----------|-----------|
| Domain | | | | |
| In TADs | 6350 | 11467 | < 2.2e-16 | 0.6147439 |
| Not in TADs | 7028 | 7802 | | |
| Boundary | | | | |
| Boundary | 2220 | 2646 | 1.13e-12 | 1.24991 |
| Not Boundary | 11158 | 16623 | | |
| Promoter | | | | |
| Promoter | 581 | 859 | 0.622 | 0.9730338 |
| Non promoter | 12797 | 18410 | | |
| Enhancer | | | | |
| Enhancer | 71 | 636 | < 2.2e-16 | 0.1563255 |
| Non enhancer | 13307 | 18633 | | |

The associations between switch/non-switch sites and 4 factors, including TAD domain, boundary, promoter and enhancer, were analyzed by two-sided fisher's exact test.

Supplementary Table 2. Multivariate analysis of *PD-L1* expression.

| <i>Predictors</i> | <i>CD274</i> | | | | | |
|-------------------|-----------------|-------------------|---------------|------------------|-----------------|-----------|
| | <i>Estimate</i> | <i>std. Error</i> | <i>CI</i> | <i>Statistic</i> | <i>P</i> | <i>df</i> |
| (Intercept) | -8.16 | 0.71 | -9.55 – -6.77 | -11.57 | 2.14e-27 | 470.00 |
| STAT1 | 1.12 | 0.04 | 1.04 – 1.20 | 26.47 | 3.43e-95 | 470.00 |
| STAG2 | -0.13 | 0.06 | -0.24 – -0.01 | -2.17 | 3.02e-02 | 470.00 |

Observations 473

R² / R² adjusted 0.609 / 0.608

After adjusting for STAT1 expression, *STAG2* was an independent negative predictor of CD274 expression ($\beta = -0.13$, $P = 3.02e-02$). *P* values were determined by two-sided alternative hypothesis test.